China Isotope & Radiation Corp. (HK:1763) has released an update.
China Isotope & Radiation Corporation (CIRC) has announced the successful introduction and implementation of the medical therapeutic nuclide Terbium-161 (Tb-161) in the PRC, a first in the country. This nuclide is noted for its promising applications in nuclear medicine due to its suitable half-life and potent anti-tumor effects, potentially offering enhanced treatment options for patients with certain primary tumors and micrometastases. The development is anticipated to keep PRC’s nuclear medicine research in step with global advancements and could lead to broader patient benefits in the future.
For further insights into HK:1763 stock, check out TipRanks’ Stock Analysis page.
